Inhibikase Therapeutics, Inc.
IKT
$1.94
-$0.15-7.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 71.69% | 36.22% | |||
| Gross Profit | -71.69% | -36.22% | |||
| SG&A Expenses | 250.21% | -17.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 121.86% | 15.38% | |||
| Operating Income | -121.86% | -15.38% | |||
| Income Before Tax | -109.98% | -16.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -109.98% | -16.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -109.98% | -16.50% | |||
| EBIT | -121.86% | -15.38% | |||
| EBITDA | -121.99% | -15.40% | |||
| EPS Basic | 74.13% | 1.17% | |||
| Normalized Basic EPS | 74.13% | 1.14% | |||
| EPS Diluted | 74.13% | 1.17% | |||
| Normalized Diluted EPS | 74.13% | 1.14% | |||
| Average Basic Shares Outstanding | 711.39% | 17.87% | |||
| Average Diluted Shares Outstanding | 711.39% | 17.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||